作为二次进展性多发性硬化症用siponimod治疗的不良影响的外周:一个案例系列
Edward H Chang1, Todd A Hardy2
1MS & Neuroimmunology Clinics, Concord Repatriation General Hospital, University of Sydney, NSW, Sydney, Australia.
Journal of neuroimmunology
|March 17, 2024
概括
周围胀是西波尼莫德的潜在副作用,西波尼莫德是一种治疗二级渐进性多发性硬化症 (SPMS) 的药物. 这种与西波尼莫德相关的外周胀可能会导致不运动,需要临床注意.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 像西波尼莫德一样,氨酸1-酸盐受体 (S1P) 调节剂用于治疗次级渐进性多发性硬化症 (SPMS).
- 周围水是已知的一些S1P调节器的潜在不良影响.
研究的目的:
- 在SPMS患者中报告与西波尼莫德治疗相关的外周胀病例.
- 为了突出西波尼莫德诱导的外周胀的临床意义和潜在的发病率.
主要方法:
- 一系列病例报告了三名SPMS患者用siponimod治疗.
- 在开始服用西波尼莫德后,临床观察新的或恶化的外周.
主要成果:
- 三名SPMS患者在开始服用siponimod后出现了新的或恶化的外周.
- 在一名患者中,外周胀导致不动.
结论:
- 与西波尼莫德相关的外周是临床相关的不良事件,需要得到认可.
- 在开始西波尼莫德治疗之前,临床医生应评估患者是否有先前存在的胀和危险因素.
相关概念视频
Local Anesthetics: Adverse Effects
414
While local anesthetics are generally safe and well-tolerated, they can occasionally cause adverse effects that vary in severity. Local anesthetics can induce toxicity at two distinct levels. They can either produce local effects through direct contact with the neural elements or be absorbed into the bloodstream from the injection site, leading to systemic effects.
Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...
Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...
414
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
156
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
156
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
161
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
161
Pleural Effusion II: Symptoms and Management
166
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
166
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
176
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
176
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
164
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
164


